Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of innovative therapeutics for chronic liver diseases. Its flagship product, Ocaliva, is approved for treating primary biliary cholangitis (PBC), a rare and chronic liver disease. The company is also working on other product candidates to treat nonalcoholic steatohepatitis (NASH), a more common and serious liver disease. Intercept's mission is to enhance the quality of life for patients with liver diseases by advancing groundbreaking therapies that target the root causes of these conditions. With headquarters in New York City and operations in the United States, Europe, and Canada, Intercept is committed to making a positive impact on the lives of patients worldwide.